Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer

Fig. 1

Molecular profiling of RMs and patient outcome. (a) Model of liquid biopsy (LB) and tissues analyses for early prediction of recurrence. TP53 mutational status and expression of the prognostic microRNAs signature have been assessed in resection margins (RMs) and LB samples from representative HNSCC patients by NGS, qPCR and dPCR. The combination of TP53 status and microRNAs expression in histologically tumor-free RMs and in sera samples taken at different time points (i.e., before and after surgery) may early predict tumor persistence or the risk of local recurrence in HNSCC. (b-c) Kaplan-Meier (KM) analyses of RMs according to (b) TP53 mutational status (wt or mutated, red or blue, respectively) or (c) the TP53 p.P72R polymorphism (P or R allele, red or blue, respectively). P72-positive RMs includes patients with P allele VAF > 75% while R72-positive RMs contains samples harboring heterozygous P/R or homozygous R alleles. CI values (95%) are shown within parenthesis. (d) Merged KM analyses resulting from TP53 mutational status and P72R polymorphism. (e) Representative model of TP53 abundance (VAF, brown cells) dynamics in tumor and resection margins. CDS: coding sequence; HR: hazard ratio; RFS: recurrence-free survival; VAF: variant allele frequency; wt: wild type; mut = mutated. *: p = 0.06; **: p = 0.006

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us